Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia.

Autor: Mazziotta F; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD., Biavati L; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD., Rimando J; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD., Rutella S; John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, United Kingdom., Borcherding N; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO., Parbhoo S; School of Electrical and Electronic Engineering, Imperial College London, London, United Kingdom., Mukhopadhyay R; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD., Chowdhury S; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD., Knaus HA; Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria., Valent P; Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria., Hackl H; Division of Bioinformatics, Biocenter, Medical University of Innsbruck, Innsbruck, Austria., Borrello IM; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD., Blazar BR; Division of Blood & Marrow Transplant and Cellular Therapy, Masonic Cancer Center and Department of Pediatrics, University of Minnesota, Minneapolis, MN., Hatzi K; Genentech, Inc, South San Francisco, CA., Gojo I; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD., Luznik L; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD.

Publikováno v: Blood [Blood] 2024 Sep 12; Vol. 144 (11), pp. 1168-1182.

Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 Years.

Autor: Webster JA; National Heart Lung and Blood Institute, University School of Medicine, Baltimore, Maryland. Electronic address: jwebst17@jhmi.edu., Reed M; National Heart Lung and Blood Institute, University School of Medicine, Baltimore, Maryland., Tsai HL; National Heart Lung and Blood Institute, University School of Medicine, Baltimore, Maryland., Ambinder A; National Heart Lung and Blood Institute, University School of Medicine, Baltimore, Maryland., Jain T; National Heart Lung and Blood Institute, University School of Medicine, Baltimore, Maryland., Dezern AE; National Heart Lung and Blood Institute, University School of Medicine, Baltimore, Maryland., Levis MJ; National Heart Lung and Blood Institute, University School of Medicine, Baltimore, Maryland., Showel MM; National Heart Lung and Blood Institute, University School of Medicine, Baltimore, Maryland., Prince GT; National Heart Lung and Blood Institute, University School of Medicine, Baltimore, Maryland., Hourigan CS; National Heart Lung and Blood Institute, University School of Medicine, Baltimore, Maryland., Gladstone DE; National Heart Lung and Blood Institute, University School of Medicine, Baltimore, Maryland., Bolanos-Meade J; National Heart Lung and Blood Institute, University School of Medicine, Baltimore, Maryland., Gondek LP; National Heart Lung and Blood Institute, University School of Medicine, Baltimore, Maryland., Ghiaur G; National Heart Lung and Blood Institute, University School of Medicine, Baltimore, Maryland., Dalton WB; National Heart Lung and Blood Institute, University School of Medicine, Baltimore, Maryland., Paul S; National Heart Lung and Blood Institute, University School of Medicine, Baltimore, Maryland., Fuchs EJ; National Heart Lung and Blood Institute, University School of Medicine, Baltimore, Maryland., Gocke CB; National Heart Lung and Blood Institute, University School of Medicine, Baltimore, Maryland., Ali SA; National Heart Lung and Blood Institute, University School of Medicine, Baltimore, Maryland., Huff CA; National Heart Lung and Blood Institute, University School of Medicine, Baltimore, Maryland., Borrello IM; National Heart Lung and Blood Institute, University School of Medicine, Baltimore, Maryland., Swinnen L; National Heart Lung and Blood Institute, University School of Medicine, Baltimore, Maryland., Wagner-Johnston N; National Heart Lung and Blood Institute, University School of Medicine, Baltimore, Maryland., Ambinder RF; National Heart Lung and Blood Institute, University School of Medicine, Baltimore, Maryland., Luznik L; National Heart Lung and Blood Institute, University School of Medicine, Baltimore, Maryland., Gojo I; National Heart Lung and Blood Institute, University School of Medicine, Baltimore, Maryland., Smith BD; National Heart Lung and Blood Institute, University School of Medicine, Baltimore, Maryland., Varadhan R; National Heart Lung and Blood Institute, University School of Medicine, Baltimore, Maryland., Jones RJ; National Heart Lung and Blood Institute, University School of Medicine, Baltimore, Maryland., Imus PH; National Heart Lung and Blood Institute, University School of Medicine, Baltimore, Maryland.

Publikováno v: Transplantation and cellular therapy [Transplant Cell Ther] 2023 Mar; Vol. 29 (3), pp. 182.e1-182.e8. Date of Electronic Publication: 2022 Dec 29.

Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study.

Autor: El-Khoury H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Lee DJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Alberge JB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Redd R; Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Cea-Curry CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Perry J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Barr H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Murphy C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Sakrikar D; The Binding Site, Rochester, MN, USA., Barnidge D; The Binding Site, Rochester, MN, USA., Bustoros M; Department of Medical Oncology, Weill Cornell Medicine, New York, NY, USA., Leblebjian H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Pharmacy, Dana-Farber Cancer Institute, Boston, MA, USA., Cowan A; Alix School of Medicine, The Mayo Clinic, Rochester, MN, USA., Davis MI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Amstutz J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Boehner CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Lightbody ED; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Sklavenitis-Pistofidis R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Perkins MC; The Binding Site Group, Birmingham, UK., Harding S; The Binding Site Group, Birmingham, UK., Mo CC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Kapoor P; The Mayo Clinic, Rochester, MN, USA., Mikhael J; Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA; International Myeloma Foundation, North Hollywood, CA, USA., Borrello IM; Department of Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Fonseca R; Department of Medical Oncology, The Mayo Clinic, Phoenix, AZ, USA., Weiss ST; Harvard Medical School, Boston, MA, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Karlson E; Harvard Medical School, Boston, MA, USA; Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Trippa L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Rebbeck TR; The Center for Prevention of Progression of Blood Cancer, Dana-Farber Cancer Institute, Boston, MA, USA., Getz G; Harvard Medical School, Boston, MA, USA; Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Marinac CR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; The Center for Prevention of Progression of Blood Cancer, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; The Center for Prevention of Progression of Blood Cancer, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: irene_ghobrial@dfci.harvard.edu.

Publikováno v: The Lancet. Haematology [Lancet Haematol] 2022 May; Vol. 9 (5), pp. e340-e349. Date of Electronic Publication: 2022 Mar 25.